Le Foll B, Tang V, Rueda S, Trick L, Boileau I
J Clin Invest. 2024; 134(20).
PMID: 39403927
PMC: 11473150.
DOI: 10.1172/JCI172887.
Feingold D, Tzur Bitan D, Ferri M, Hoch E
Eur Arch Psychiatry Clin Neurosci. 2024; 275(2):341-353.
PMID: 38493284
DOI: 10.1007/s00406-024-01781-4.
Hall W, Manthey J, Stjepanovic D
Eur Arch Psychiatry Clin Neurosci. 2024; 275(2):307-313.
PMID: 38489067
DOI: 10.1007/s00406-024-01776-1.
Shekhawat A, Mathur R, Sarkar S, Kaloiya G, Balhara Y
J Neurosci Rural Pract. 2023; 14(4):710-716.
PMID: 38059244
PMC: 10696312.
DOI: 10.25259/JNRP_79_2023.
Bidzinski K, Lowe D, Sanches M, Sorkhou M, Boileau I, Kiang M
Schizophrenia (Heidelb). 2022; 8(1):2.
PMID: 35210458
PMC: 8873399.
DOI: 10.1038/s41537-022-00210-6.
A psychometric assessment of the Brief Situational Confidence Questionnaire for Marijuana (BSCQ-M) in juvenile justice-involved youth.
Micalizzi L, Sokolovsky A, Delaney D, Gunn R, Hernandez L, Kemp K
Addict Behav. 2021; 125:107154.
PMID: 34735980
PMC: 8662708.
DOI: 10.1016/j.addbeh.2021.107154.
Assessing Changes in Symptoms of Depression and Anxiety During Four Weeks of Cannabis Abstinence Among Adolescents.
Cooke M, Gilman J, Lamberth E, Rychik N, Tervo-Clemmens B, Evins A
Front Psychiatry. 2021; 12:689957.
PMID: 34276449
PMC: 8280499.
DOI: 10.3389/fpsyt.2021.689957.
Momentary coping and marijuana use in treated adults: Exploring mechanisms of treatment.
Litt M, Kadden R, Tennen H, Dunn H
J Consult Clin Psychol. 2021; 89(4):264-276.
PMID: 34014689
PMC: 8211388.
DOI: 10.1037/ccp0000633.
Motivation and Problem Solving (MAPS): Motivationally Based Skills Training for Treating Substance Use.
Vidrine J, Reitzel L, Figueroa P, Velasquez M, Mazas C, Cinciripini P
Cogn Behav Pract. 2020; 20(4):501-516.
PMID: 33239855
PMC: 7685295.
DOI: 10.1016/j.cbpra.2011.11.001.
Treating cannabis use disorder: Exploring a treatment as needed model with 34-month follow-up.
Stephens R, Walker R, DeMarce J, Lozano B, Rowland J, Walker D
J Subst Abuse Treat. 2020; 117:108088.
PMID: 32811637
PMC: 7478338.
DOI: 10.1016/j.jsat.2020.108088.
Clinical and cost-effectiveness of contingency management for cannabis use in early psychosis: the CIRCLE randomised clinical trial.
Rains L, Marston L, Hinton M, Marwaha S, Craig T, Fowler D
BMC Med. 2019; 17(1):161.
PMID: 31412884
PMC: 6694526.
DOI: 10.1186/s12916-019-1395-5.
Individualized assessment and treatment program (IATP) for cannabis use disorder: Randomized controlled trial with and without contingency management.
Litt M, Kadden R, Tennen H, Petry N
Psychol Addict Behav. 2019; 34(1):40-51.
PMID: 31318225
PMC: 6980271.
DOI: 10.1037/adb0000491.
Cannabis and Its Secondary Metabolites: Their Use as Therapeutic Drugs, Toxicological Aspects, and Analytical Determination.
Goncalves J, Rosado T, Soares S, Simao A, Caramelo D, Luis A
Medicines (Basel). 2019; 6(1).
PMID: 30813390
PMC: 6473697.
DOI: 10.3390/medicines6010031.
Sequential and simultaneous treatment approaches to cannabis use disorder and tobacco use.
Lee D, Walker D, Hughes J, Brunette M, Scherer E, Stanger C
J Subst Abuse Treat. 2019; 98:39-46.
PMID: 30665602
PMC: 6366318.
DOI: 10.1016/j.jsat.2018.12.005.
Systematic review of outcome domains and measures used in psychosocial and pharmacological treatment trials for cannabis use disorder.
Lee D, Schlienz N, Peters E, Dworkin R, Turk D, Strain E
Drug Alcohol Depend. 2018; 194:500-517.
PMID: 30530238
PMC: 7038155.
DOI: 10.1016/j.drugalcdep.2018.10.020.
Integrated cognitive behavioral therapy for comorbid cannabis use and anxiety disorders: A pilot randomized controlled trial.
Buckner J, Zvolensky M, Ecker A, Schmidt N, Lewis E, Paulus D
Behav Res Ther. 2018; 115:38-45.
PMID: 30442329
PMC: 6409106.
DOI: 10.1016/j.brat.2018.10.014.
The Effects of the Addiction Programme of Probation on Treatment Motivation, Abstinence and Quality of Life: a Comparative Study with Motivational Interviewing and Individual Intervention.
Aldemir E, Berk G, Coskunol H
Noro Psikiyatr Ars. 2018; 55(3):261-270.
PMID: 30224874
PMC: 6138221.
DOI: 10.5152/npa.2017.19440.
Contingency management intervention targeting co-addiction of alcohol and drugs among American Indian adults: Design, methodology, and baseline data.
Burduli E, Skalisky J, Hirchak K, Orr M, Foote A, Granbois A
Clin Trials. 2018; 15(6):587-599.
PMID: 30156433
PMC: 6218308.
DOI: 10.1177/1740774518796151.
A review of contingency management for the treatment of substance-use disorders: adaptation for underserved populations, use of experimental technologies, and personalized optimization strategies.
McPherson S, Burduli E, Smith C, Herron J, Oluwoye O, Hirchak K
Subst Abuse Rehabil. 2018; 9:43-57.
PMID: 30147392
PMC: 6095117.
DOI: 10.2147/SAR.S138439.
Impact of cannabis legalization on treatment and research priorities for cannabis use disorder.
Sahlem G, Tomko R, Sherman B, Gray K, McRae-Clark A
Int Rev Psychiatry. 2018; 30(3):216-225.
PMID: 29956576
PMC: 6322658.
DOI: 10.1080/09540261.2018.1465398.